| Regenerative Medical Technology Group Inc. (RMTG) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | |||||||||||||||||||||||||||||||
| Fiscal Period | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | |||||||||||||||||||||||||||||||
| Price to Sales | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Book | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Earnings | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Unlevered FCF | |||||||||||||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | 7.65x | 7.47x | 8.06x | 8.16x | 9.28x | 9.47x | 8.72x | 8.57x | 2.48x | 7.66x | 29.79x | 80.58x | 179.61x | 575.89x | 276.68x | 1,852.53x | 99.23x | 1,729.47x | 132.04x | 326.95x | |||||||||||||||||||||||||||||
| Current Ratio | .09x | .06x | .05x | .04x | .03x | .03x | .03x | .03x | .14x | .69x | .05x | .01x | .01x | - | - | - | .01x | - | .01x | - | |||||||||||||||||||||||||||||